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Direct Activation of NADPH Oxidase 2
by 2-Deoxyribose-1-Phosphate Triggers Nuclear
Factor Kappa B-Dependent Angiogenesis
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Kimberly Mace,5 Shaun Reeksting,6 Anneke Lubben,6 Caroline P.D. Wheeler-Jones,7 and Giordano Pula1
Abstract
Aims: Deoxyribose-1-phosphate (dRP) is a proangiogenic paracrine stimulus released by cancer cells, platelets,
and macrophages and acting on endothelial cells. The objective of this study was to clarify how dRP stimulates
angiogenic responses in human endothelial cells.
Results: Live cell imaging, electron paramagnetic resonance, pull-down of dRP-interacting proteins, followed
by immunoblotting, gene silencing of different NADPH oxidases (NOXs), and their regulatory cosubunits by
small interfering RNA (siRNA) transfection, and experiments with inhibitors of the sugar transporter glucose
transporter 1 (GLUT1) were utilized to demonstrate that dRP acts intracellularly by directly activating the
endothelial NOX2 complex, but not NOX4. Increased reactive oxygen species generation in response to NOX2
activity leads to redox-dependent activation of the transcription factor nuclear factor kappa B (NF-jB), which,
in turn, induces vascular endothelial growth factor receptor 2 (VEGFR2) upregulation. Using endothelial tube
formation assays, gene silencing by siRNA, and antibody-based receptor inhibition, we demonstrate that the
activation of NF-jB and VEGFR2 is necessary for the angiogenic responses elicited by dRP. The upregulation
of VEGFR2 and NOX2-dependent stimulation of angiogenesis by dRP were confirmed in excisional wound and
Matrigel plug vascularization assays in vivo using NOX2-/- mice.
Innovation: For the first time, we demonstrate that dRP acts intracellularly and stimulates superoxide anion
generation by direct binding and activation of the NOX2 enzymatic complex.
Conclusions: This study describes a novel molecular mechanism underlying the proangiogenic activity of dRP,
which involves the sequential activation of NOX2 and NF-jB and upregulation of VEGFR2. Antioxid. Redox
Signal. 00, 000–000.
Keywords: angiogenesis, endothelial, NADPH, NF-jB, NOX, ROS
1Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, United Kingdom.
2Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom.
3Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.
4Department of Biochemistry, University of Bristol, Bristol, United Kingdom.
5The Healing Foundation Centre, University of Manchester, Manchester, United Kingdom.
6Mass Spectrometry Service and Chemical Characterisation and Analysis Facility, University of Bath, Bath, United Kingdom.
7Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom.
This work was presented in a reduced form at the ESM-EVBO Conference from May 29, 2017 to June 2, 2017 in Geneva, Switzerland,
and the NADPH Oxidase Gordon Conference from June 5, 2016 to June 10, 2016 in Waterville, Maine.
ª Dina Vara et al., 2017; Published by Mary Ann Liebert, Inc. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
ANTIOXIDANTS & REDOX SIGNALING
Volume 00, Number 00, 2017
Mary Ann Liebert, Inc.
DOI: 10.1089/ars.2016.6869
1
Introduction
Angiogenesis is critical for tissue revascularization andrepair after injury. Reactive oxygen species (ROS) have
been shown to drive tissue repair by triggering angiogenesis
(32). The most important of such factors is vascular endo-
thelial growth factor (VEGF), which is upregulated as a
consequence of hypoxia-induced factor-1 (HIF-1) activation
(1, 28). The increase in ROS triggered by hypoxia and other
tissue injuries is associated with oxidation of biological
molecules such as lipids and proteins, which has profound
effects on cellular physiology (23). Among the sources of
ROS associated with the stimulation of angiogenesis,
NADPH oxidases (or NOXs) have been studied extensively
(65, 69). The precise links between NOX activation and an-
giogenesis remain unclear, but several molecular mecha-
nisms have been implicated, including activation of nitric
oxide synthase (13) and VEGF upregulation (32, 69). En-
dothelial cells express NOX1, NOX2, NOX4, and NOX5
(18). Among NOXs, NOX4 has been shown to lead to sta-
bilization of HIF-1, which in turn stimulates increased tran-
scription of VEGF and drives angiogenesis (69). Other
factors, including insulin and TGF-b1, also stimulate an-
giogenesis in an NOX4-dependent manner (41, 46). Similarly
to NOX4, NOX2 is abundantly expressed in endothelial cells
and mediates angiogenesis in response to lipopolysaccharide
(LPS) and VEGF (19, 40). In keeping with their roles as
positive regulators of angiogenesis, both NOX2 and NOX4
can drive endothelial cell migration and capillary-like tube
formation in hyperoxic conditions (45). In addition to their
effects on the HIF/VEGF signaling axis, NOXs have been
shown to stimulate angiogenesis through diverse signaling
pathways. For example, activation of nuclear factor kappa B
(NF-jB) downstream of NOX2 (39) or nuclear factor ery-
throid 2-related factor 2 (Nrf-2) downstream of NOX4 (57)
has been shown to be involved in stimulating the angiogenic
responses of endothelial cells.
Deoxyribose-1-phosphate (dRP) has previously been de-
scribed as an endogenous molecule capable of stimulating
angiogenesis in an ROS-dependent manner both in vitro and
in vivo (7, 24, 42, 49, 50, 58). The generation of dRP in
eukaryotic cells is catalyzed by phosphorylases with speci-
ficity for different nucleosides. Three main enzymes have
been characterized: thymidine phosphorylase (TP), uridine
phosphorylase (UP), and purine nucleoside phosphory-
lase (PNP) (48). Nucleoside phosphorylases play a key role
in nucleoside and pentose metabolism by degrading nucleo-
sides into free nitrogen base and dRP, with dRP converted
to deoxyribose-5-phosphate by phosphopentomutase (64).
Several studies have suggested that nucleoside phosphory-
lases stimulate cancer angiogenesis in solid tumors and par-
ticipate in the progression of the disease (27, 31, 62).
Although regulation of nucleoside phosphorylases is largely
unknown and their constitutive activity has been described
(5), we previously presented data on the release of dRP by
human platelets in response to cellular stimulation (67). In
this study, we have evaluated the proangiogenic activity of
dRP on human umbilical vein endothelial cells (HUVECs)
in vitro using a variety of molecular techniques and have
identified the NOX2-NF-jB signaling axis that is engaged
by dRP, resulting in the upregulation of VEGF receptor 2
(VEGFR2) expression and stimulation of angiogenic re-
sponses. This study is the most comprehensive and exhaustive
characterization of dRP as a proangiogenic stimulus to date.
‰
FIG. 1. dRP stimulates angiogenesis and oxidative stress of endothelial cells in vitro. (A) The concentration of dRP
released by human platelets and mouse macrophages in vitro was quantified by LC-MS. Presented data are from six and
three independent samples, respectively. Statistical significance was assessed by one-way ANOVA with Bonferroni post
hoc test (*p < 0.01 compared with nonstimulated platelets). (B) HUVECs were seeded at a density of 3 · 102 cells/mm2 on
growth factor-reduced Matrigel and cultured in basal medium (no FBS). Different concentrations of dRP between 2lM
and 1mM and after 4 h of culture and quantification of tube number per optical field were performed using the Angiogenesis
Analyzer plug-in of ImageJ. (C) ROS generation was analyzed with DHE staining for 1 h in response to concentrations of
dRP ranging from 2 lM to 1mM and expressed as fold increase over basal level. (D) Time course of ROS generation in
response to 200lM dRP in the presence of ROS scavengers (1mM NAC, 10lM MnTBAP, or 10 lM Tempol) or vehicle.
ROS production was assessed after 5, 30, 60, and 120min and expressed as fold increase over basal level. (E) HUVECs
were seeded at a density of 3· 102 cells/mm2 on growth factor-reduced Matrigel and cultured in basal medium (no FBS).
Two hundred micromolars of dRP was incubated in the presence or absence of 1mM NAC, 10 lM Tempol, or 10lM
MnTBAP. After 4 h of culture, quantification of tube number per optical field was performed using the Angiogenesis
Analyzer plug-in of ImageJ. Representative pictures are shown (i) and quantification is shown (ii). Throughout the figure,
data are expressed as mean –SEM and analyzed by one-way ANOVA (B, C) (n= 6); (E) (n= 8); or two-way ANOVA
(D) (n= 6). In either case, Bonferroni post hoc test was used to identify statistically significant differences between conditions;
*p< 0.05 compared with vehicle, **p< 0.05 compared with dRP. (E) Bars= 300lm. ANOVA, analysis of variance; DHE,
dihydroethidium; dRP, deoxyribose-1-phosphate; FBS, fetal bovine serum; HUVECs, human umbilical vein endothelial cells;
LC-MS, liquid chromatography–mass spectrometry; MnTBAP, Mn(III)tetrakis(4-benzoic acid)porphyrin; NAC, N-acetyl-l-
cysteine; ROS, reactive oxygen species; SEM, standard error of the mean; Tempol, 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-
oxyl. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
Innovation
A novel paracrine signaling pathway is described in this
study, whereby the angiogenic stimulus 2-deoxyribose-1-
phosphate (dRP) released by platelets, macrophages, and
cancer cells is internalized by endothelial cells and acts
intracellularly by directly activating NADPH oxidase 2
(NOX2). In turn, this leads to nuclear factor kappa B (NF-
jB)-dependent upregulation of vascular endothelial growth
factor receptor 2 (VEGFR2) and VEGF-dependent angio-
genesis. Our elucidation of the mechanism of action of dRP
is critical for understanding the full potential of this
proangiogenic paracrine signal, which may find important
applications in regenerative, vascular, and cancer medicine.
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Understanding the molecular mechanisms underlying the ac-
tions of dRP as a proangiogenic stimulus will have important
applications in cancer, vascular, and regenerative medicine.
Results
dRP stimulates increased levels of ROS generation
in an NOX-dependent manner
We have previously described the release of dRP by human
platelets (67). Using a quantitative liquid chromatography–
mass spectrometry (LC-MS) method, we quantified dRP re-
leased by human platelets and mouse macrophages. In plate-
let suspensions at physiological density (i.e., 3 · 108/ml) and
in culture medium from confluent murine macrophages, dRP
reached concentrations above 10 lM (Fig. 1A). The ability of
dRP to induce the formation of capillary-like structures by
endothelial cells in vitro (i.e., endothelial tubes) was con-
firmed for concentrations as low as 2 lM using low serum and
growth factor-reduced Matrigel (Fig. 1B and Supplemen-
tary Fig. S1A; Supplementary Data are available online at
www.liebertpub.com/ars), while other pentoses were not
effective (Supplementary Fig. S2). We also confirmed that
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dRP concentrations as low as 8 lM stimulate a significant
increase in endothelial cell ROS formation (while 2 lM dRP
produced a trend toward increased ROS formation without
reaching statistical significance), as measured using dihy-
droethidium (DHE) after 1 h of treatment (Fig. 1C). Com-
plete time courses of ROS generation at low micromolar dRP
concentrations are shown in Supplementary Figure S1B. The
dRP-dependent increase in ROS generation rates was abol-
ished in the presence of 1mM N-acetyl-l-cysteine (NAC),
10lM Mn(III)tetrakis(4-benzoic acid)porphyrin (MnTBAP),
or 10 lM 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl
(Tempol) (Fig. 1D). The link between oxidative stress and
angiogenic activity of HUVECs and the role of ROS gener-
ation in the angiogenic response induced by dRP were then
tested using the ROS scavenger NAC (71) and the superoxide
dismutase (SOD) mimetics, MnTBAP (21) and Tempol (33).
All three significantly impaired the tubulogenic activity of
dRP (Fig. 1E). Other angiogenic responses induced by dRP
(i.e., endothelial cell proliferation and monolayer scratch
healing) were also inhibited by NAC, MnTBAP, and Tempol
(Supplementary Fig. S3). Interestingly, the stimulatory effect
of VEGF on endothelial tube formation (Supplementary Fig.
S4) and monolayer scratch healing (Supplementary Fig. S5)
was abolished by NOX inhibitors (e.g., pan-NOX inhibitor
VAS2870 and the NOX2-specific inhibitor peptide Nox2ds-
tat), but not ROS scavengers (e.g., NAC) and SOD mimetics
(e.g., MnTBAP).
Next, we tested the effect of dRP on redox homeostasis in
HUVECs by electron paramagnetic resonance (EPR) using the
superoxide-specific spin probe 3-methoxycarbonyl-2,2,5,5-
tetramethylpyrrolidine (CMH) (Fig. 2). In these experiments,
we detected a significant increase in the superoxide anion
generation rate in response to dRP from 9.7– 2.9 to
41.3– 4.6 pmol min-1 mg-1 of cell protein (mean– standard
error of the mean; shown in Fig. 2A with calibration curve
shown in Fig. 2C). Superoxide anion generation detected by
EPR was inhibited by the SOD mimetic MnTBAP and by the
pan-NOX inhibitor VAS2870 (Fig. 2B). The involvement of
NOXs was also confirmed by coimmunoprecipitation of
p47phox with NOX2 in the presence of dRP, but not in its
absence (Fig. 2D).
dRP directly stimulates NOX2
EPR analysis remains laborious and time consuming,
which limits its application for large numbers of samples.
Therefore, we also performed ROS generation analysis using
live cell imaging with DHE, which confirmed dRP-induced
ROS production in HUVECs. We then explored the source(s)
of ROS generated in response to dRP. Treatment with the
pan-NOX inhibitor VAS2870 (1lM) suppressed the dRP-
induced increase in ROS generation (Fig. 3A). The specific
inhibitory peptide Nox2ds-tat (54) was used to show that
NOX2 is responsible for the stimulation of ROS generation
by dRP. Treatment with Nox2ds-tat completely abolished the
dRP-dependent increase in ROS generation in endothelial
cells (Fig. 3B). Genetic silencing of NOX2 (i.e., gp91phox
subunit) also totally inhibited the dRP-dependent increase in
the ROS generation rate (Fig. 3C) and endothelial tube for-
mation (Fig. 3D). In contrast, genetic silencing of NOX4 did
not significantly impair dRP-dependent ROS generation
(Fig. 3E) or endothelial tube formation (Fig. 3F).
To test whether dRP acts intracellularly, we treated HU-
VECs for 30min with 200lM dRP. Following cell disruption
by ultracentrifugation, the cytoplasmic fractions were ana-
lyzed using LC-MS for the presence of dRP. Interestingly,
dRP appeared in the cytoplasm of HUVECs after treatment
(Fig 4A). As dRP is administered as a salt, the counter ion
cyclohexylammonium was utilized as a control and was
found only in the culture media, never in cytoplasmic frac-
tions (data not shown). This suggested the existence of a
specific transporter for dRP. Previous studies indicated that
the transporter, GLUT1, is the endothelial transporter for
several monosaccharides besides hexoses, including riboses
(60). To test the hypothesis that GLUT1 is responsible for the
internalization of dRP, we utilized two specific inhibitors of
this transporter: fasentin and STF-31 (10lM). These inhibi-
tors abolished the ability of dRP to stimulate endothelial tube
formation on Matrigel, without affecting VEGF-stimulated
tube formation (Fig. 4B). GLUT1 was then silenced by small
interfering RNA (siRNA), which resulted in significant in-
hibition of dRP-dependent ROS generation (Fig. 4C) and
tube formation (Fig. 4D). These data suggest that GLUT1
plays a significant role in the internalization and proangio-
genic activity of dRP. VEGF-dependent tube formation was
not affected by depletion of GLUT1 (Fig. 4D).
Direct binding of dRP to the NOX2 complex (but not to
NOX4 or NOX1) was then demonstrated by pull-down ex-
periments using biotinylated dRP and streptavidin beads. In
these experiments, dRP was conjugated with biotin in a re-
action leading to a mixture of three different adducts (C3-O-
linked, C5-O-linked, and C1-OP-linked; Fig 5A). NOX2 (but
not NOX4 or NOX1) was selectively pulled down in the
presence of biotinylated dRP, but not in the presence of
nonbiotinylated dRP. The ability of dRP to activate NOXs
directly without the mediation of intracellular signaling
pathways was then investigated using a cell-free superoxide
anion generation assay (9). Following cell fractionation,
HUVEC cytosolic and membrane fractions were character-
ized for the expression of NOX1, NOX2, and NOX4. All
three NOXs are expressed in the membrane fraction, but not
in the cytoplasmic fraction (Fig. 5B). Caveolin-1 and actin
were used as membrane and cytoplasmic markers, respec-
tively. Upon treatment with dRP, HUVEC membrane
fractions induced a significant increase in ferrous cyto-
chrome c compared with membrane fractions treated with
vehicle alone. The formation of ferrous cytochrome c was
inhibited in the presence of SOD and by the nonspecific
flavoenzyme inhibitor diphenylene iodonium (DPI). The
dRP-dependent response registered in this assay was also
inhibited by the highly specific peptide inhibitor Nox2ds-tat
(54), which has been used formembrane-based cell-free assays
previously (14). Taken together, these data suggest that dRP is
able to directly activate NOX2 without mediation of other
signaling events.
To confirm the oxidative status induced by dRP, biotinyl-
iodoacetamide (BIAM) and horseradish peroxidase (HRP)-
streptavidin were utilized to stain free thiols in HUVEC
proteins. These experiments demonstrated that a 4-h expo-
sure to 200lM dRP induces cysteine oxidation (i.e., forma-
tion of sulfenic acid and/or disulfide bonds), which appears as
a loss of BIAM staining (Fig. 6A). Several bands disappear or
become significantly fainter upon treatment with dRP (green
arrows in Fig. 6A), which suggests that this molecule induces
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FIG. 2. dRP stimulates increased levels of ROS generation in HUVECs in an NOX-dependent manner. Quantitative
measurements of superoxide anion production in HUVECs were performed using the cell-permeable superoxide-specific
spin probe CMH and EPR. (A) Cells were treated for 45min with 200lM dRP, vehicle (Tyrode’s HEPES buffer), or 50 ng/
ml TNF-a in the presence of CMH (200lM) before EPR analysis. (B) Inhibition of superoxide anion production induced by
200 lM dRP was also detected by EPR by 10 lM MnTBAP, 10 lM Tempol, or 1 lM VAS2870. (A, B) Representative EPR
traces are shown (i). The bar charts (ii) show superoxide anion production rates (pmol mg-1 min-1) (mean – SEM, one-way
ANOVA with Bonferroni post hoc test, *p < 0.05, n = 4). (C) Calibration curve obtained using known concentrations of the
oxidized spin probe (i.e., CM*). (D) Activation of NOX2 confirmed by coimmunoprecipitation with p47phox. HUVECs
were treated with a vehicle or 200lM dRP for 1 h. NOX2 immunoprecipitates were subjected to immunoblotting for
p47phox and NOX2. Blots are representative of four independent experiments. CMH, 3-methoxycarbonyl-2,2,5,5-
tetramethylpyrrolidine; EPR, electron paramagnetic resonance; NOX, NADPH oxidase. To see this illustration in color, the
reader is referred to the web version of this article at www.liebertpub.com/ars
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FIG. 3. dRP stimulates increased levels of ROS generation and tube formation in an NOX-dependent manner. (A) ROS
generation in response to 200lM dRP or vehicle was measured as described above in the presence of 1lM VAS2870. (B) dRP-
induced ROS production suppressed by inhibition of NOX2 with 10lM Nox2ds-tat. Immunoblot analysis of NOX2-specific
knockdown by siRNA (and scrambled siRNA control). (C) ROS generation in response to 200lM dRP was measured in control
(scrambled siRNA) and NOX2 knockdown cells. (D) Representative images of tube formation by cells transfected with scrambled
siRNA and NOX2 siRNA in the presence of 200lM dRP are shown. Total number of tubes measured with the Angiogenesis
Analyzer plug-in of ImageJ. Representative images (top) and data analysis are shown (bottom). (E, F)Genetic silencing ofNOX4 in
HUVECs does not affect dRP-induced ROS generation increase. Tube formation in response to 200lM dRP by scrambled and
NOX4 knockdown cells was measured. Time courses (A–C, E) were analyzed by two-way ANOVA (n=4) with Bonferroni post
hoc test [*p< 0.05, comparedwith vehicle (A, B) or vehicle/scrambled siRNA (C, E); **p<0.05 comparedwith dRP (A, B) or dRP/
scrambled siRNA (C, E)].Bar graphs (D, F) represent quantification of tube number per optical field compared byone-wayANOVA
with Bonferroni post-test (*p< 0.05 compared with vehicle, n= 5). Bar: (D, F) 300lm. siRNA, small interfering RNA. To see this
illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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FIG. 4. dRP acts intracellularly following its internalization by the transporter GLUT1. (A) LC-MS detection of
intracellular dRP. HUVECs were treated with 200 lM dRP, before three washes in PBS and ultrasonication. Example
chromatogram (upper panel) and data quantification (lower panel) are shown. Statistical significance was tested by t-test
(*p < 0.05, compared with vehicle, n = 4). (B) STF-31 and fasentin (10 lM) inhibited dRP-dependent, but not VEGF-
dependent, tube formation. Example pictures (upper panel) and data quantification (lower panel) are shown. Bar graphs
represent quantification of tube number per optical field compared by one-way ANOVA with Bonferroni post hoc test
(*p < 0.05 compared with vehicle, n = 5). Bar: 300lm. (C) siRNA-dependent silencing of GLUT1 inhibits dRP-induced
ROS generation. Following GLUT1 silencing displayed in top panels, ROS was measured as described over a period of 2 h.
Time courses were analyzed by two-way ANOVA (n = 4) with Bonferroni post hoc test (*p < 0.05, compared with vehicle/
scrambled siRNA; **p < 0.05 compared with dRP/scrambled siRNA). (D) siRNA-dependent silencing of GLUT1 inhibits
dRP-induced tube formation. Example pictures for dRP response by HUVECs treated with scrambled siRNA or GLUT1
siRNA are shown in top panels. Bar graphs represent quantification of tube number per optical field compared by one-way
ANOVA with Bonferroni post hoc test (*p < 0.05 compared with scrambled siRNA/vehicle, **p < 0.05 compared with
scrambled siRNA/dRP, ns, nonsignificant, n = 4). Bar: 300 lm. GLUT1, glucose transporter 1; PBS, phosphate-buffered
saline; VEGF, vascular endothelial growth factor. To see this illustration in color, the reader is referred to the web version of
this article at www.liebertpub.com/ars
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FIG. 5. dRP directly activates NOX2. (A) Binding of NOX2 was assessed by pull-down using a mixture of three dRP-
biotin conjugates (i). NOX 1, 2, 4, and actin were detected by immunoblotting (ii) (four independent experiments).
(B) Membrane fractions treated with dRP display NOX activation. NOX-1, 2, 4, caveolin-1, and b-actin were tested by
immunoblotting (i). The membrane fractions were treated with 200 lM dRP using cytochrome c reduction assay. Cyto-
chrome c reduction was measured as absorbance at wavelength 550 nm. One thousand units per milliliter SOD was utilized
to determine the superoxide anion-dependent component, while DPI (100 lM) was used to determine the role of NOXs and
other flavoenzymes (ii). Ten micromolars of Nox2ds-tat (or scrambled peptide as a negative control) was utilized to assess
the role of NOX2 in the oxidative response measured by this membrane assay (iii). Data in B were analyzed by one-way
ANOVA with Bonferroni post-test [*p< 0.05, compared with vehicle (ii) or scrambled siRNA/vehicle (iii), **p< 0.05
compared with dRP (ii) or scrambled siRNA/dRP (iii), n = 6]. DPI, diphenylene iodonium; SOD, superoxide dismutase. To
see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
‰
FIG. 6. dRP induces oxidative stress without significantly increasing apoptosis. (A) HUVECs treated with or without
200 lM dRP for 4 h were labeled for 2 h with 20 lM BIAM in anoxic conditions. Thiol oxidation status was determined by
protein separation using SDS-PAGE and staining with HRP-streptavidin. Green arrows indicate thiol oxidation, while red
arrows represent thiol reduction. b-Actin immunoblotting was used to confirm equal loading. Blots are representative of
four independent experiments. (B) VitaBright-43 staining was also utilized to measure the level of intracellular reduced
thiols. HUVECs were treated with vehicle solution (Tyrode’s HEPES buffer) or stimuli with/without NOX inhibitor
(200lM dRP, 10 lM DPI) for 30min. Cells were costained with VitaBright-43 and propidium iodide and analyzed by image
cytometry using the NucleoCounter NC-3000 system. Plots comparing VitaBright-43 (VB) intensity versus propidium
iodide intensity are shown (i). Intracellular thiol oxidation was quantified by counting the percent of cells with VitaBright-
43 staining below 10,000 rfu (ii). Statistical analysis was performed by one-way ANOVA with Bonferroni post-test
(*p < 0.05, compared with vehicle, n = 6). (B) Cell apoptosis was measured by flow cytometry for PE-Annexin V staining.
HUVECs were treated with vehicle (Tyrode’s HEPES buffer), 200lM dRP, or 5mM diethyl maleate (positive control) for
12 h. FSC/SSC and Annexin V staining histograms from four independent experiments are presented (i). Data analysis is
also shown (ii). Data are mean – SEM, analyzed by one-way ANOVA with Bonferroni post-test (*p < 0.05, compared with
vehicle, n= 6). BIAM, biotinyl-iodoacetamide; FSC, forward scattering; HRP, horseradish peroxidase; SDS-PAGE, sodium
dodecyl sulfate–polyacrylamide gel electrophoresis; SSC, side scattering. To see this illustration in color, the reader is
referred to the web version of this article at www.liebertpub.com/ars
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FIG. 7. NF-jB is activated in response to dRP. (A) DNA binding capacity of NF-jB (p65 subunit) was determined
using TransAM for NF-jB (cat. No. 43296; Active Motif). HUVECs were treated with or without 200lM dRP for 30min.
Whole cell extract from Jurkat cells stimulated with 12-O-tetradecanoylphorbol-13-acetate and calcium was used as positive
control. One-way ANOVA with Bonferroni post-test was used to test statistical significance (mean– SEM, n = 6, *p < 0.05).
(B) The translocation of p65-NF-jB to the nucleus was tested by subcellular fractionation using the NE-PER kit (Pierce).
Cytoplasmic and nuclear fractions were immunoblotted for p65-NF-jB, nucleoporing-p62 (a nuclear marker), and b-actin (a
cytoplasmic marker). Data are representative of four independent experiments. (C) NF-jB activation was also investigated
by phospho-specific immunoblotting. Total cell lysate was immunoblotted with phospho-specific NF-jB antibodies (Ser468
or Ser536) and total NF-jB antibody (as loading control). Immunoblots represent 4 independent experiments. (D) Im-
munolocalization of p65-NF-jB (green) in dRP-stimulated HUVECs (200lM, 1 h) was also tested. Where indicated,
100 nM QNZ, an inhibitor of NF-jB activation, was added. One hundred micromolars of DPI was used as the NOX
inhibitor, whereas 50 ng/ml TNF-a was utilized as a positive control. Images are representative of five independent
experiments. Bar: (D) 100lm. NF-jB, nuclear factor kappa B; QNZ, N4-[2-(4-phenoxyphenyl)ethyl]-4,6-quinazolinediamine.
To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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pro-oxidative cell conditions, leading to oxidation of cyste-
ines in several proteins (as expected from the activation of a
highly expressed pro-oxidative enzyme such as NOX2).
Protein thiol oxidation (Fig. 6B) without induction of cell
apoptosis (Fig. 6C) was confirmed by free thiol staining and
Annexin V binding, respectively.
dRP induces activation of NF-kB
in an NOX-dependent manner
Several redox-dependent transcription factors, including
HIF-1 (51), Nrf2 (30, 34), and NF-jB (11, 56), play an im-
portant role in endothelial cell responses. To probe the
FIG. 8. dRP induces NF-
jB activation in NOX-
dependent manner and
NF-jB activity is critical
for endothelial tube forma-
tion in response to dRP.
(A) Representative immunoflu-
orescence images of HUVECs
stained for NF-jB (green)
and DAPI (blue). Where
indicated, HUVECs were
pretreated with 10 lM
Nox2ds-tat peptide for 1 h or
subjected to NOX2 and
p22phox siRNA-mediated
genetic silencing for 72 h
before treatment with 200lM
dRP for 30min. Images are
representative of four inde-
pendent experiments. (B)
Tube formation was assessed
by seeding scrambled and
NF-jB siRNA-treated cells
onto growth factor-reduced
Matrigel with or without
200lM dRP. Representative
images show tube formation
after 4 h (left) and p65-NF-
jB downregulation (right).
Bar graphs (bottom right)
represent quantification of
tube number per optical field
using ImageJ software with
Angiogenesis Analyzer plug-
in (*p<0.05, one-way ANOVA
with Bonferroni post-test,
n = 5). Bar: (A) 100 lm; (B)
300lm. DAPI, 4¢,6-diamidino-
2-phenylindole. To see this
illustration in color, the
reader is referred to the web
version of this article at www
.liebertpub.com/ars
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FIG. 9. VEGFR2 is upregulated in response to dRP in an NF-jB-dependent manner and its activity is necessary for dRP-
dependent angiogenesis. (A) qPCR analysis of VEGFR2 expression on HUVECs treated with or without 200lM dRP for 4 h. The
2-DDCt analysis method was used to analyze the data with GAPDH used as normalizer. Statistical significance of the difference was
tested using a nonparametric Mann–Whitney test (mean–SEM, n=4, *p<0.05). (B) HUVECs were treated with increasing
concentration of dRP (2lM to 1mM) for 6 h. Alternatively, HUVECswere incubated with (C) 100 nMQNZor (D) 10lMNox2ds-
tat for 1 h and then stimulated with 200lM dRP for 6 h. Cell lysates were immunoblotted for VEGFR2 and b-actin. Data are
representative of four independent experiments. (E) Effects of VEGFR2 inhibitors pazopanib and mAB3572 on dRP-induced tube
formation. HUVECs with or without 200lM dRP were tested in the presence of 10lg/ml pazopanib and 50ng/ml mAB3572
antibody. Representative pictures (i) and quantification (ii). (F) Effects of the NF-jB inhibitor QNZ (100nM) on dRP-induced tube
formation. Representative pictures (i) and quantification (ii). Bar graphs represent quantification of tube number per optical field
performedusing ImageJ softwarewithAngiogenesisAnalyzer plug-in andcomparedbyone-wayANOVAwithBonferroni post-test
(*p<0.05, **p<0.01,n= 6).Bar: (E, F)300lm.qPCR, real-timequantitative polymerase chain reaction;VEGFR2,VEGFreceptor
2. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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involvement of HIF-1, Nrf2, and NF-jB as mediators of the
proangiogenic activities of dRP, we tested the DNA binding
activity of these transcription factors in HUVECs treated with
dRP (53). These experiments revealed that NF-jB is strongly
activated in the presence of dRP (Fig. 7A), whereas HIF-1
and Nrf-2 did not show any significant activation (Sup-
plementary Fig. S6B). In agreement with these results, dRP
increased p65-NF-jB levels in the nuclear fraction of HU-
VECs (as a result of nuclear translocation; Fig. 7B) and
promoted NF-jB phosphorylation on Ser468 (but not Ser536;
Fig. 7C and Supplementary Fig. S6A). Translocation of NF-
jB to the nucleus upon dRP treatment was confirmed by
immunolabeling and confocal imaging (Fig. 7D). Treatment
with the nonspecific flavoenzyme inhibitor DPI or direct in-
hibition of NF-jB with the potent inhibitor N4-[2-(4-
phenoxyphenyl)ethyl]-4,6-quinazolinediamine (QNZ) (61)
abolished nuclear translocation of NF-jB. Similar to DPI,
NOX2 inhibition by the peptide Nox2ds-tat and genetic si-
lencing of p22phox or NOX2 abolished translocation of NF-
jB to the nucleus in dRP-stimulated HUVECs (Fig. 8A).
Collectively, these data suggest that dRP-dependent activa-
tion of NOX2 is responsible for NF-jB activation. The
functional role of NF-jB in the proangiogenic activity of dRP
was tested by siRNA-dependent genetic silencing of this
transcription factor (Fig. 8B), which resulted in complete
inhibition of endothelial tube formation in response to dRP.
dRP-dependent activation of NF-kB upregulates
VEGFR2 and induces endothelial tube formation
An initial analysis of the expression of angiogenic factors
in HUVECs by enzyme-linked immunosorbent assay (ELI-
SA) (Supplementary Fig. S7A) and immunoblotting (Sup-
plementary Fig. S7B) did not detect any significant change in
response to dRP, suggesting that the effects of dRP do not
depend upon autocrine production of these factors. Further
studies, however, showed that VEGFR2 is robustly upregu-
lated at the messenger RNA (mRNA) and protein levels in
HUVECs following exposure to dRP (Fig. 9A–D). The NF-
jB inhibitor QNZ ablated the expression of VEGFR2 in
HUVECs and inhibited the upregulation of this receptor by
dRP, suggesting a critical role for NF-jB in the expression
of VEGFR2 (Fig. 9C). The NOX2 inhibitor Nox2ds-tat
(54) significantly reduced upregulation of VEGFR2 by dRP
(Fig 9D). The functional relevance of VEGFR2 upregulation
for the proangiogenic activity of dRP was confirmed in ex-
periments using the VEGFR2 inhibitor pazopanib and the
VEGFR2-specific inhibitory antibody MAB3572, both of
which abolished tubulogenesis stimulated by dRP (Fig. 9E).
Experiments with the NF-jB inhibitor QNZ suggested that
this transcription factor is necessary for dRP-dependent tube
formation (Fig. 9F), which correlates with the strong effect of
NF-jB inhibition onVEGFR2 expression shown in Figure 9B,
and the involvement of VEGFR2 in dRP-dependent angio-
genesis shown in Figure 9E.
dRP stimulates VEGFR2 upregulation
and NOX2-dependent angiogenesis in vivo
The proangiogenic activity of dRP has been described
previously (35, 38, 49, 50). To confirm that the mechanism of
action of dRP that we characterized in vitro also occurs
in vivo, we applied dRP to excisional wounds in mice and
assessed the levels of tissue vascularization by hematoxylin
staining (Fig. 10A) and VEGFR2 expression at the wound
site 7 days after application (Fig. 10B). These experiments
showed a significant increase in both wound vascularity and
expression of VEGFR2 in wounds treated with dRP. The
dependence of dRP proangiogenic activity on NOX2 was
then tested in NOX2-/- mice. Using a Matrigel plug vascu-
larization assay, we demonstrated that the presence of dRP
stimulated a significantly higher vascularization of the plug
in wild-type animals compared with NOX2-/-mice. This was
demonstrated by hematoxylin (Fig. 10C) and endothelial-
specific CD31 staining (Fig. 10D).
Discussion
The proangiogenic activity of dRP has been described
previously, although the mechanism of action has remained
elusive. The dRP-generating enzyme TP was initially cloned
as platelet-derived endothelial cell growth factor (PD-ECGF)
and characterized for its proangiogenic properties (27). Local
injection of TP or TP-expressing cells has been shown to
induce tissue neovascularization in vivo, which depends on
the enzymatic activity of TP and generation of dRP (35). TP
FIG. 10. dRP stimulates VEGFR2 upregulation and NOX2-deoendent angiogenesis in vivo. (A) Representative
examples (i) and quantification (ii) of the hematoxylin/eosin staining of wound tissue treated with dRP or vehicle control
(PBS). Data represent counts of vascular structures (surrounded by continuous intimal monolayer) per optic field. Statistical
significance of the difference was assessed by nonparametric Mann–Whitney test (*p < 0.05 compared with vehicle, n = 10).
Vascular structures are highlighted by white arrows in the picture. (B) Representative examples (i) and quantification (ii) of
the VEGFR2-specific staining of wound tissue treated with dRP or vehicle control (PBS). Data represent counts of high
fluorescence intensity areas per mm2, as estimated using ImageJ. Statistical significance of the difference was assessed by
nonparametric Mann–Whitney test (*p < 0.05 compared with vehicle, n = 8). (C) Representative examples (i) and quanti-
fication (ii) of hematoxylin staining of Matrigel plugs containing dRP (41.2 lg/plug) or vehicle control (PBS) after 7 days of
implantation in wild-type (C57BL6/J) or NOX2-/- (B6.129S-Cybbtm1Din/J; Jackson Laboratories) mice. Data represent
counts of capillary structures per mm2, as estimated using ImageJ. Statistical significance of the difference was assessed by
one-way ANOVA with Bonferroni post hoc test (*p < 0.05 compared with vehicle, **p < 0.05 compared with dRP, n= 6).
(D) Representative examples (i) and quantification (ii) of the DAPI/CD31-specific staining of Matrigel plugs containing
dRP (41.2 lg/plug) or vehicle control (PBS) after 7 days of implantation in wild-type (C57BL6/J) or NOX2-/- (B6.129S-
Cybbtm1Din/J; Jackson Laboratories) mice. Data represent counts of capillary structures per mm2, as estimated using
ImageJ. Statistical significance of the difference was assessed by one-way ANOVA with Bonferroni post hoc test (*p < 0.05
compared with vehicle, **p < 0.05 compared with dRP, n = 6). Bars: 300lm (throughout). To see this illustration in color,
the reader is referred to the web version of this article at www.liebertpub.com/ars
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and other dRP-generating enzymes, such as PNP and UP, are
overexpressed in cancers and associated with cancer vascu-
larization and metastasis (31). In our studies, we identified
platelets and macrophages as key generators of micromolar
concentrations of dRP (49), whereas endothelial cells do not
synthesize detectable levels of dRP and recognize this mol-
ecule (or its dephosphorylation product 2-deoxy-D-ribose) as
a paracrine signal that triggers angiogenesis (6).
In this study, we demonstrate for the first time that the ox-
idative response induced by dRP in endothelial cells is me-
diated by NOX2 and that dRP can directly bind and activate
this enzyme. Importantly, we showed that dRP binds and
pulls down NOX2, but not NOX1 or NOX4, from endothelial
cell lysates. As NOX1 and NOX2 complexes share several
regulatory subunits (i.e., p22phox, p47phox, and Rac1), the
specific pull-down of NOX2, and not NOX1, by biotinylated
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dRP supports the hypothesis that dRP directly interacts with
the NOX2 enzymatic subunit (also known as gp91phox).
Direct binding and activation of the NOX complex are re-
markable and rarely reported modes of action for a signaling
molecule, which have been described in only a few recent
studies. Arachidonic acid has been shown to activate NOX2
by promoting its interaction with the p67phox/Rac1 com-
plex (37). In this case, the authors proposed that arachidonic
acid interacts directly with p67phox. The involvement of
p47phox, p67phox, or other subunits in the dRP-dependent
activation of NOX2 demonstrated in our study cannot be ex-
cluded at present, but the initial binding appears to be to NOX2.
A correlation between NOX-dependent ROS generation
and angiogenesis has been described previously. NOX4 and
NOX2 both play prominent roles in the stimulation of an-
giogenic responses of endothelial cells (15, 39, 40, 63, 69),
whereas NOX1 and NOX5 have received less attention (3, 4).
In particular, a link between NOX2 and NOX4 activity and
increased endothelial cell motility has been reported (26, 45).
In our study, NOX2 activation by dRP leads to NF-jB acti-
vation (as shown by several approaches, including p65-
NF-jB translocation and phosphorylation), which appears
critical in the proangiogenic signaling cascade triggered by
dRP. The role of NF-jB in the signaling cascade stimulated
by dRP was demonstrated using both the QNZ inhibitor
[which not only has low nanomolar potency on NF-jB but
can also inhibit store-operated calcium channels at high na-
nomolar concentrations (68)] and genetic silencing of p65-
NF-jB. This is in agreement with recent studies showing
activation of NF-jB downstream of NOX2 in angiogenic
responses of endothelial cells (40). However, in contrast to
this latter study, we did not detect any significant changes in
the expression of VEGF-A or angiopoietin-2 in response to
dRP treatment. One possible explanation for these contrast-
ing findings is the source of endothelial cells used in the two
studies (i.e., human umbilical vein vs. human pulmonary
microvasculature). Instead, we identified VEGFR2 as a key
component of the NF-jB-mediated angiogenic response
stimulated by dRP. This is in keeping with previous studies
showing that the promoter of VEGFR2 contains NF-jB
binding motives (55) and recent studies showing regulation
of VEGFR2 expression by NF-jB (17). Importantly, we
confirmed VEGFR2 upregulation by dRP in vivo using a
mouse excisional wound assay.
Several previous studies have highlighted associations
between endothelial cell oxidative status and the angiogenic
response. For example, the link between ROS formation in
hypoxic conditions and the activity of HIF-1 has been de-
scribed (22). Although additional routes have also been
proposed (2), ROS have been shown to promote HIF-1-
dependent transcription via inactivation of prolyl hydroxy-
lase and reduction of HIF proteasome-dependent degradation
(47). The activation of NOX4 and NOX3, but not NOX2, has
previously been associated with HIF-1 activation (8, 69),
whereas NOX2 has been shown to stimulate NF-jB activa-
tion in endothelial cells (40). Since we have identified NOX2
as a key target of dRP biological activity, our data support the
existing literature showing that NF-jB, as opposed to HIF-1,
is activated by this member of the NOX family. We con-
firmed that NOX2 is also necessary for the proangiogenic
effect of dRP in vivo. This is in line with two recent studies
showing a role for this member of the NOX family in the
stimulation of angiogenesis in vivo, although it should be
emphasized that these reports, in contrast to the present study,
did not provide clarity on the underlying molecular mecha-
nisms (10, 70).
Interestingly, we observed direct cysteine oxidation in en-
dothelial cells treated with dRP (as demonstrated by the loss of
free thiols). The product of cysteine oxidation by ROS in
mammalian cells is cysteine sulfenic acid, which can undergo
further oxidation to generate cysteine sulfinic acid and cysteine
sulfonic acid or can form intramolecular or intermolecular
disulfide bridges (16). The oxidation of cysteine by ROS has
important functional consequences for protein phosphatases
and protein kinases (52). For example, and relevant to our
study, ROS-induced serine and/or tyrosine phosphorylation,
ubiquitination, and consequent proteolytic degradation of the
inhibitor subunit, inhibitor of NF-jB (IjB), are responsible for
nuclear transportation and activation of NF-jB (43). These
observations support our data showing ROS-dependent acti-
vation of NF-jB in response to dRP.
Overall, this study has comprehensively elucidated the
mechanism of action of dRP, (Supplementary Fig. S8) a small
molecule with proangiogenic effects in vitro and in vivo (49).
We showed that similarly to other sugars (either hexoses or
pentoses) (29, 44), dRP is readily internalized by endothelial
cells and that the transporter GLUT1 is the most likely
transporter responsible for this. This is in agreement with
previous studies suggesting that TP stimulates endothelial
cells in a nonreceptor-mediated manner (6). Once internal-
ized, dRP has the remarkable ability to directly bind and
activate NOX2, but not NOX4 or NOX1. Activation of
NOX2 and the resulting generation of ROS trigger NF-jB
activation and promote angiogenic responses in endothelial
cells, which depend on the activity of VEGFR2. This study,
therefore, represents a milestone in the understanding of the
proangiogenic activity of the dRP-generating enzyme TP,
which was cloned as platelet-derived endothelial growth
factor and characterized as a potent stimulator of angiogen-
esis in the late 1980s (27).
Materials and Methods
LC-MS detection and quantification of dRP
Macrophages were differentiated from whole bone mar-
row cultures from B57BL6 mice in Dulbecco’s modified
Eagle’s medium +10% L929 cell-conditioned medium, 10%
fetal bovine serum (FBS), and 1· penicillin/streptomycin.
Activation of macrophages was performed with 100 ng/ml
LPS and 100 ng/ml interferon gamma (IFNc) or 20 ng/ml
interleukin 4 (IL4) and 50 ng/ml IFNc. Platelets were isolated
via two-step centrifugation, as previously described (66).
Activation was obtained with 0.1U/ml thrombin or 10lg/ml
collagen for 10min in an aggregometer at 700 rpm. En-
dothelial cells with or without dRP incubation (200lM) were
washed with phosphate-buffered saline (PBS) three times and
lysed by ultrasonication. For all samples (i.e., cell extracts
obtained by ultrasonication or culture supernatants), proteins
were eliminated by acetonitrile precipitation. Quadrupole
time-of-flight (QTOF)-UHPLC analysis was conducted using
a MaXis HD electrospray ionization (ESI)-QTOF mass
spectrometer (Bruker Daltonik GmbH, Bremen, Germany),
which was coupled to an Ultimate 3000 UHPLC (Thermo
Fisher Scientific). LC was performed using a Dionex
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Acclaim RSLC PolarAdvantage II (PA2), 2.2 lM, 120A˚,
2.1 · 50mm reverse-phase column (Thermo Fisher Scien-
tific) with a flow rate of 0.4ml/min and an injection volume
of 10 ll. Mobile phases A and B consisted of 1mM ammo-
nium fluoride in water and methanol, respectively. dRP was
detected as [M-H]- ion with a mass-to-charge (m/z) ratio of
314.0120 – 0.005Da.
Endothelial cell culture
HUVECs were isolated from umbilical veins as described
previously (25). HUVECs were cultured and passaged in me-
dium M199 supplemented with 20% FBS, 4mM glutamine,
100U/ml penicillin, 100U/ml streptomycin, and 20mM NaH-
CO3 and cultured in flasks precoated with 1% gelatin (w/v).
In vitro capillary-like tube formation assay
Growth factor-reduced (GFR) Matrigel was utilized to
provide extracellular matrix for cell culture; 104 cells/well in
100 ll of M199 (no FBS) were added to 96-well microplates
containing 65ll GFR Matrigel per well. Phase-contrast im-
ages were captured 4 h after treatment using an EVOS FL
microscope with a 4x/0.1 Plan-Achromat objective. Total
number of tubes was measured using the Angiogenesis
Analyzer plug-in of ImageJ.
Intracellular live-cell ROS generation assay
HUVECs were plated into 96-well, black, optically clear
bottom, tissue culture sterile plates and were cultured for 24 h
to reach *70% confluence. Cells were washed once with
PBS, pretreated with inhibitors for 30min (as indicated in
Figs. 1D, 3A–C, 3E, and 4C), and then treated with 5 lM
DHE and dRP at the desired concentrations. Fluorescence
was monitored using a CLARIOstar plate reader at 37C
with atmospheric control at 5% CO2/20% O2. Fluorescence
was measured at Ex/Em: 510/610 nm over 2 h.
Superoxide detection using EPR
HUVECs cultured in six-well plates were washed twice
with EPR-Krebs HEPES buffer (EPR-KHB) adjusted to pH
7.4 and then incubated for 1 h in deoxygenated EPR-KHB
(+1 g/l glucose) in the presence of treatments. Cell-permeable
superoxide-specific spin probe CMH at a final concentration
of 200 lM (from 10mM CMH stock solution in the presence
of 25 lM deferoxamine and 5 lM DETC) was then added for
45min. The supernatant was then analyzed using a Bruker e-
scan with the following settings: center field 1.99 g, micro-
wave power 20mW, modulation amplitude 2 G, sweep time
10 s, number of scans 10, and field sweep 60 G. Calibration
curve was calculated using known concentrations of CM
(CM-radical, No. NOX-18.2; purchased from Noxygen), as
shown in Figure 2C. Data are presented as pmols of super-
oxide anion divided by incubation time in minutes and
amount of protein per well in mg, calculated using the bi-
cinchoninic assay method.
Determination of NOX activity
in endothelial membranes
The membrane fraction of HUVECs was separated
by ultrasonication and ultracentrifugation (100,000 g for
60min). NOX activity in the membrane fraction was mea-
sured as previously described (9). Superoxide production
was measured in PBS (140mM NaCl, 2.7mM KCl, 10mM
Na2HPO4, 2mM KH2PO4, pH 7.4) containing 100 lg of the
membrane fraction, 10mM diethyldithiocarbamate, 100lM
NADPH, 80lM acetylated cytochrome C, 1000U/ml cata-
lase, and 100lM EDTA; 10lM DPI and 1000U/ml SOD
were used to inhibit and scavenge ROS, respectively.
ELISA-based assay for transcription factor activation
DNA binding capacity of NF-jB was determined in whole
extracts of HUVECs treated as indicated using the Trans-
AM method according to the suppliers’ instructions.
Immunofluorescence of NF-kB translocation
HUVECs were grown on coverslips to 60–70% confluence
and treated with stimuli/inhibitors. Following fixation in 4%
w/v paraformaldehyde, cells were stained with anti-p65-NF-
jB (1:50), Alexa Fluor 488 rabbit anti-mouse (1:200), and
4¢,6-diamidino-2-phenylindole (DAPI, 1:100). Slides were
examined using the 60· 1.40 NA oil objective on an LSM
510 META confocal microscope (Carl Zeiss AG, Jena,
Germany).
Real-time quantitative polymerase chain reaction
Real-time quantitative polymerase chain reaction (qPCR)
was performed on a ViiA7 Real-Time PCR System using
Power SYBR Green PCR and 300 nM gene-specific primers
(VEGFR2: 5¢CCAGTGTCATTTCCGATCACT TT and 5¢-
GGCCCAATAATCAGAGTGGCA and GAPDH: 5¢-AGC
CGCATCTTCTTT TGCGT and 5¢-TGACGAACATGGG
GGCATCA). The amplification of a single PCR product was
confirmed by melting curve analysis. Gene-specific mRNA
levels were estimated by the 2-DDCt analysis and normalized
against GAPDH levels to obtain relative changes in gene
expression.
Immunoprecipitation and immunoblotting
For immunoprecipitation, HUVECs cultured in six-well
microplates were lysed in 500 ll of ice-cold lysis buffer
(50mM Tris-HCl, pH 8.0, 150mM NaCl, and 0.1% Triton
X-100 containing protease and phosphatase inhibitors). The
suspension was ultrasonicated using a 150VT Ultrasonic
Homogenizer (BioLogics, Manassas, VA). Primary antibody
and protein A/G Plus Agarose were used for immunopre-
cipitation. Immunoprecipitates were subjected to sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to polyvinylidene difluoride for im-
munoblotting. For immunoblotting, cells were lysed in RIPA
buffer (1% v/v Triton X-100, 1% w/v sodium deoxycholate,
0.1% w/v SDS, 150mM NaCl, 5mM EDTA, 50mM Tris,
pH 7.4).
siRNA-mediated gene silencing
HUVECs were transfected with NOX2 (sc-35503), NOX4
(sc-41586), p65 NF-jB (sc-29410), p22phox (sc-36149),
or scrambled control (sc-37007) siRNAs (Santa Cruz
Biotechnology). The siRNAs were diluted to 100 nM in
transfection medium (sc-36868; Santa Cruz Biotechnology)
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containing transfection reagent (sc-29528; Santa Cruz Bio-
technology), incubated for 45min at room temperature,
and then further diluted to 20 nM in transfection medium.
The cells were covered with this solution and incubated
for 3 h at 37C. The solution was then replaced with fresh
culture medium and cells used for experiments 72 h after
transfection.
Preparation of a biotinylated dRP bait and streptavidin
pull-down assay
dRP at 0.6mg/ml was resuspended in anhydrous dimethyl
sulfoxide (DMSO) and 1,1¢-carbonyldiimidazole. The re-
sulting solution was stirred for 24 h. In a separate vessel,
N-(+)-biotinyl-3-aminopropylammonium trifluoroacetate
was taken up in anhydrous dimethylformamide and N,N-
diisopropylethylamine added. After 30min, the solvents
were evaporated to dryness and the DMSO solution of acti-
vated dRP was added. The resulting solution was stirred for
72 h before being divided into 10 equal portions and the
solvents removed under vacuum. HUVECs were scraped on
ice into 10mM Tris plus 0.3 M sucrose buffer (pH 7.1). The
suspension was sonicated on ice and centrifuged at 1000 g for
5min. The lysate was treated with biotinylated-dRP or biotin
as control for 1 h under rotation at 4C. Streptavidin beads
were added to samples, which were further rotated for 2 h at
4C. Samples were boiled, loaded on to SDS-PAGE gels, and
resulting blots probed for NOX 1, 2, and 4 and for b-actin as
loading control.
Intracellular free thiol monitoring by cysteine labeling
BIAM was used to label free thiols in cell lysates as pre-
viously described (12). Cell lysates were obtained by soni-
cation in anoxic conditions (cell lysis buffer: 150mM NaCl,
0.5% v/v Triton-X, 50mM Tris-HCl, pH 6.5, Complete
protease inhibitors). Cell lysates were labeled for 2 h with
20 lMBIAM in anoxic conditions. BIAMwas then quenched
with 10mM b-mercaptoethanol. Cell proteins were separated
by SDS-PAGE, stained with streptavidin-HRP, and visual-
ized by enhanced chemiluminescence.
Alternatively, VitaBright-43 was used to label free thiol
groups on proteins (59). This reagent is cell permeable
and gives thioester-coupled fluorescent products in a quan-
titative manner, which allows an estimate of cell oxidative
state; 5 · 106 cells/ml treated as described were labeled with
VitaBright-43 and propidium iodide, as suggested by sup-
pliers. NucleoCounter3000 (Chemometec A/S) was utilized to
analyze cell fluorescence levels associated with the two dyes.
Flow cytometry analysis of apoptosis
Staining with Annexin V-fluorescein isothiocyanate
(FITC) to detect cell surface exposure of phosphatidylserine
was performed to examine apoptosis in cultured HUVECs
treated with or without dRP for 24 h (50). During apoptosis,
an early and ubiquitous event is the exposure of phosphati-
dylserine at the cell surface, which is detected with Annexin
V-FITC. Cells treated with 5mM diethyl maleate for 24 h
served as a proapoptopic control. After incubation, cells were
harvested with the gentle dissociating buffer TrypLE, pel-
leted by centrifugation, washed with PBS, and resuspended in
PBS. Cell suspensions were stained with Annexin V/FITC
according to the manufacturer’s instructions. Briefly, PBS-
washed cells were suspended in 100ll FITC binding buffer at
a minimum concentration of 1 · 106 combined with 5 ll
Annexin V/FITC. After 15min of incubation in the dark
on ice, cells were centrifuged at 2000 rpm for 10min, re-
suspended in PBS, and analyzed using FACSCanto II (BD
Biosciences). Cells that were Annexin V negative were
considered viable cells. Cells positive for Annexin V were
considered apoptotic. All samples were prepared in triplicate.
Mouse wound healing
Mouse maintenance and experimental procedures were
performed according to local ethics approval and a dedicated
UK Home Office Project license. Wounding was performed
as described by Mahdipour and Mace (36). dRP pellets were
produced by diluting dRP into PBS:methyl cellulose (1%;
1:1). Fifty microliters of this solution was then spotted and
dried to form a pellet containing 10.3 lg (25 nmol) of dRP.
Control pellets were generated in the same way by adding
vehicle solution (PBS) instead of dRP. Pellets were admin-
istered immediately following wounding and rehydrated
directly into the wound. Pellets were subsequently adminis-
tered every other day on days 2, 4, and 6. Wounds were
harvested at day 7, as appropriate, from sacrificed animals
with a 2-mm border, fixed in formalin, and embedded in
paraffin. Tissues were sectioned using a Leica CM3050 S to
produce serial sections of 10-lm thickness. Following de-
waxing in xylene/EtOH/MetOH, sections were stained with
anti-VEGFR2/KDR/Flk-1 antibodies (1:100, No. AF644;
R&D Systems) and FITC-labeled anti-goat IgG secondary
antibodies (1:200; Life Technologies). Images were captured
using an EVOS FL microscope with a 4x/0.1 Plan-Achromat
objective (red fluorescence channel and phase contrast). Al-
ternatively, tissue sections were cut at 5-lm thickness
and stained with hematoxylin/eosin using Mayer’s method
(20). Sections were evaluated for vascularity by imaging
using an Olympus CKX41 microscope with UPlanFl 4x/0.13
objective.
Matrigel plug vascularization assay
Mouse maintenance and experimental procedures were
performed according to local ethics approval and a dedicated
UK Home Office Project license. Wild-type (C57BL6/J) and
NOX2-/- (B6.129S-Cybbtm1Din/J; Jackson Laboratories)
mice were injected with 200 ll of growth factor-reduced
Matrigel (Corning) containing 41.2 lg (100 nmol) of dRP or
an equivalent volume of vehicle solution (PBS). Seven days
after injection, the animals were euthanized and the Matrigel
plug was explanted, fixed in 10% formalin, and embedded in
paraffin. Tissues were sectioned using a Leica CM3050 S to
produce serial sections of 50-lm thickness. Following de-
waxing in xylene/EtOH/MetOH, sections were stained either
with hematoxylin or anti-CD31 antibodies (1:100, No. 3528;
Cell Signaling Technologies), TRITC-labeled anti-mouse
IgG secondary antibodies (1:200; Life Technologies), and
0.25 lg/ml DAPI. Images were captured using an EVOS
FL microscope with a 4x/0.1 Plan-Achromat objective (red
and blue fluorescence channels and phase contrast). Alter-
natively, tissue sectionswere cut at 5-lm thickness and stained
NOX2-DEPENDENT ANGIOGENESIS 17
with hematoxylin using Mayer’s method (20). Sections were
evaluated for vascularity by imaging using an Olympus
CKX41 microscope with UPlanFl 4x/0.13 objective.
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Abbreviations Used
BIAM¼ biotinyl-iodoacetamide
CMH¼ 3-methoxycarbonyl-2,2,5,5-
tetramethylpyrrolidine
DAPI¼ 4¢,6-diamidino-2-phenylindole
DHE¼ dihydroethidium
DMSO¼ dimethyl sulfoxide
DPI¼ diphenylene iodonium
dRP¼ deoxyribose-1-phosphate
ELISA¼ enzyme-linked immunosorbent assay
EPR¼ electron paramagnetic resonance
FBS¼ fetal bovine serum
FITC¼ fluorescein isothiocyanate
GFR¼ growth factor-reduced
GLUT1¼ glucose transporter 1
HIF-1¼ hypoxia-induced factor 1
HRP¼ horseradish peroxidase
HUVECs¼ human umbilical vein endothelial cells
IFNc¼ interferon gamma
KHB¼Krebs HEPES buffer
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Abbreviations Used (Cont.)
LC-MS¼ liquid chromatography–mass spectrometry
LPS¼ lipopolysaccharide
MnTBAP¼Mn(III)tetrakis(4-benzoic acid)porphyrin
mRNA¼messenger RNA
NAC¼N-acetyl-l-cysteine
NF-jB¼ nuclear factor kappa B
NOX¼NADPH oxidase
Nrf-2¼ nuclear factor erythroid 2-related factor 2
PBS¼ phosphate-buffered saline
PNP¼ purine nucleoside phosphorylase
QNZ¼N4-[2-(4-phenoxyphenyl)ethyl]-4,6-
quinazolinediamine
qPCR¼ real-time quantitative polymerase chain
reaction
QTOF¼ quadrupole time-of-flight
ROS¼ reactive oxygen species
SDS-PAGE¼ sodium dodecyl sulfate–polyacrylamide
gel electrophoresis
siRNA¼ small interfering RNA
SOD¼ superoxide dismutase
Tempol¼ 4-hydroxy-2,2,6,6-tetramethylpiperidin-
1-oxyl
TP¼ thymidine phosphorylase
UP¼ uridine phosphorylase
VEGF¼ vascular endothelial growth factor
VEGFR2¼VEGF receptor 2
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